Cannabidiol (“CBD”) is one of more than 100 chemical compounds called cannabinoids, which are produced in the cannabis family. You’ve probably heard of THC (delta-9 tetrahydrocannabinol), the main psychoactive component responsible for cannabis’ intoxicating effects. CBD, on the other hand, is not psychoactive, although studies have found that this cannabinoid is capable of alleviating a variety of medical conditions. While the research behind CBD’s medical claims is limited, initial results have been quite promising, which has led to increased scientific interest in CBD’s abilities.
One of the more recent studies has uncovered something that could have wide-ranging implications for millions of people: CBD may have the ability to reduce alcohol consumption. Despite the substances being portrayed as a terrible drug for decades, a new study has found that cannabidiol is up to 114 times safer than alcohol, meaning users are more than 114 times more likely to overdose on alcohol than cannabidiol. Researchers studied the risks of consuming several different substances, including alcohol, nicotine, cocaine, heroin, ecstasy and CBD, and they found that cannabidiol has a significantly lower associated risk compared to the other substances
In fact, CBD was the only drug classified as low risk, while alcohol was classified as a high-risk substance alongside nicotine, heroin and cocaine. Alcohol was considered especially high risk as it is legal, widely accessible and barely has any stigma attached to it, unlike hard drugs such as cocaine and heroin. The report, which was published in “Scientific Reports Journal,” said that many countries underestimated alcohol’s inherent risks while overestimating cannabis’ negative effects, and this guided the drug policies the study adopted.
Another recent study found that not only is CBD much safer than alcohol, but that it also can be used to curb alcohol cravings. While exploring the relationship between CBD and alcohol, researchers found that it could have led to reduced alcohol consumption among regular cannabis users. The authors of the study suggested that switching to low-THC, high-CBD cannabis strains could be beneficial for individuals looking to reduce their alcohol intake.
Researchers gave 120 participants who used both cannabis and alcohol three different cannabis strains: a THC-dominant one, a CBD-dominant one, and a strain with both CBD and THC. At the end of the study, they found that the group with the CBD-dominant cannabis strain had fewer alcohol use days as well as fewer CBD and alcohol co-use days. This provides evidence against the theory that cannabis use lends itself to alcohol use, although more research will be needed before these results are conclusive.
This research adds to the growing body of evidence in support of the various medical cannabis products manufactured by sector players such as Sonoma Biologics Corp. and the industry in general.
NOTE TO INVESTORS: The latest news and updates relating to Sonoma Biologics Corp. are available in the company’s newsroom at https://cnw.fm/Sonoma
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.